SYVN1 and Alzheimer disease: Both genetic knockdown and pharmacological inhibition of ELK1 were found to reduce APP amyloidogenic processing by enhancing the SYVN1-mediated ubiquitination and degradation of PS1, leading to a reduction in senile plaque formation and an improvement in synaptic and cognitive function in AD model mice.